SERUM C-REACTIVE PROTEIN LEVEL AND THE IMPACT OF CYTOREDUCTIVE SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
- 1 December 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 162 (6) , 1934-1937
- https://doi.org/10.1016/s0022-5347(05)68072-x
Abstract
Purpose: The prognosis of metastatic renal cell carcinoma is extremely poor. In this type of metastatic tumor cytoreductive surgery of the primary tumor is often performed to confirm the histologic...Keywords
This publication has 10 references indexed in Scilit:
- Kidney cancerThe Lancet, 1998
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, 1997
- Cytoreductive Surgery for Stage IV Renal Cell CarcinomaJournal of Urology, 1995
- Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response ModifiersJournal of Urology, 1995
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.Journal of Clinical Oncology, 1993
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Hormone-induced and spontaneous regression of metastatic renal cancerCancer, 1973